OEE in pharma and aerospace: reliability and demanding sectors

Sectors where compliance comes before volume

Pharmaceuticals and aerospace share a feature that sets them apart from high-volume manufacturing: compliance comes before volume. Validated processes, full traceability, strict standards, exhaustive quality controls – everything is organised to guarantee flawless reliability and quality, because the consequences of a defect, in these fields, can be dramatic. Performance here isn’t measured the same way as elsewhere. (OEE, Overall Equipment Effectiveness, is the English term for what French manufacturers call TRS.)

This priority given to compliance shapes the nature of the losses. You won’t find the same profiles here as on a high-speed consumer-goods line. Stops linked to validations, controls, batch changes and documentary requirements take up a significant place. But that doesn’t mean there’s no OEE to reclaim: you simply have to know where to look for it, which requires an adapted form of measurement.

An often high OEE, but very real losses

In these sectors, the displayed OEE is often high, which can give the feeling that there’s little left to gain. That’s a misleading impression. On the one hand, as everywhere, declared OEE tends to overstate reality as long as it rests on manual readings. On the other, on very high-value products, even a small percentage of losses represents a considerable cost.

This is a particularity of these industries: the stake isn’t so much the number of OEE points as the value of what each point represents. A stop on a pharmaceutical line or an aerospace station immobilises production whose every unit is expensive. Recovering a few points of OEE therefore has an economic impact disproportionate to the percentage at stake.

It also reframes how progress should be judged. In a high-volume plant, a one- or two-point OEE gain may be marginal; in a regulated, high-value workshop, the same two points can represent a substantial sum, because each recovered hour produces units that are individually costly. The number on the dashboard looks similar, but the economics behind it are entirely different – which is why measuring finely is justified even where the headline OEE already looks comfortable.

Reliability as the central stake

In pharma and aerospace, reliability is the central stake. An unplanned stop costs not only production time: it can compromise a batch, trigger requalification procedures, or disrupt a tightly stretched supply chain. Preventing stops therefore has a value far greater than their mere hourly impact.

Now, many breakdowns don’t arrive without warning. A gradual drift, a slowdown, a multiplication of micro-anomalies often precede the outright stop. This signature preceding the breakdown is generally readable well before the incident – provided you have continuous measurement capable of detecting it. That’s precisely what manual tracking cannot do, for lack of granularity and continuity.

Measuring continuously to prevent rather than endure

Real-time measurement brings these sectors what reliability needs: lead time. By recording stops, pace and quality continuously, to the second, it makes drifts visible before they turn into breakdowns. You move from a logic of reaction, where you endure the stop then repair it, to a logic of anticipation, where you detect the early warning sign and intervene in time.

This lead time is especially precious where every stop is costly. Detecting the drift several hours before the breakdown is the chance for a planned intervention rather than an endured stop, with all the cascading consequences it triggers in regulated environments. Continuous measurement thus becomes a direct support to reliability, and not just a performance-measurement tool.

The shift it produces is cultural as much as technical. A team that only sees breakdowns after the fact lives in a permanent reactive mode, firefighting each stop as it lands. A team that watches the pace and the micro-anomalies in real time starts to recognise the patterns that precede trouble, and gradually moves the centre of gravity from repair to prevention. In sectors where an avoided stop can be worth a whole batch, that change of posture is itself a large part of the return.

A measurement compatible with traceability requirements

In sectors this regulated, any solution must respect traceability and not interfere with validated processes. This is an advantage of the standalone measurement-layer approach: it observes the machine without integrating into the heart of the regulated process, which limits the impact on validations and documentation. It brings data without upending the existing quality architecture.

This compatibility is decisive for industries where the slightest process change can require a heavy requalification. Being able to measure performance and anticipate drifts without touching the validated core of production removes a major obstacle. Measurement is added at the surface, where it’s useful, without calling into question the compliance patiently built over time.

Practically, that means the deployment itself stays inside what these environments can accept: a sensor on the machine, installed in under an hour, with no MES project and no production stop, delivering usable data within 48 hours. The validated process is left untouched, so the measurement layer doesn’t trigger the documentation and requalification burden that any change to the regulated core would. It’s that separation – observing without intervening – that makes continuous OEE measurement realistic in pharma and aerospace at all.

From measurement to the maintenance decision

The value of continuous measurement isn’t limited to detection: it feeds the maintenance decision. By linking observed drifts to precise contexts (a piece of equipment, a time slot, a combination of parameters), it helps target interventions where they genuinely prevent costly stops, rather than following a rigid calendar disconnected from the real state of the machines.

This approach, which starts from measurement and works towards cause, is the foundation of any advanced reliability practice. Hutchinson improved its OEE from 42% to 75% with the same headcount and machines, sensor installed in under an hour. More than 450 plants across 30+ countries already monitor their OEE to the second with TeepTrak. The gain comes not from new equipment, but from the ability to see problems coming and act before they cost – which, on high-value products, radically changes the economics of production.

This anticipation logic fits naturally with the documentary requirements of these sectors. An intervention planned from a detected drift is traced, justified and integrated into quality procedures far more easily than an endured stop followed by an emergency repair. Continuous measurement therefore supports not only technical reliability: it also eases documentary control and compliance, by turning unforeseen incidents into managed, traced actions.

Reading these sectors’ benchmark with caution

Comparing the OEE of a pharmaceutical or aerospace site to another requires particular caution. Validation and traceability constraints vary greatly from one product and one site to another, so the same figure can cover very different realities. A raw benchmark, without accounting for these specifics, easily misleads.

As in every sector, the only legitimate comparison is between real OEE figures measured the same way, and it should serve to guide action rather than deliver a verdict. In these industries where unit value is high, the point isn’t to reach a reference percentage, but to make production reliable and recover points that each weigh heavily in economic terms.

Key takeaways

In pharma and aerospace, compliance comes before volume, and OEE – often high – hides specific losses whose every point has high value. Reliability is the central stake: preventing a stop is worth far more than repairing it. Real-time measurement makes the drift readable before the breakdown and offers the lead time needed to intervene in time, without touching validated processes or traceability.

Measure to prevent, rather than endure. Hutchinson improved its OEE from 42% to 75% with the same headcount and machines, sensor installed in under an hour.

FAQ

Is OEE high in pharma and aerospace?
Often, owing to the strong quality and compliance stakes, but with specific losses. And on very high-value products, even a small percentage of losses represents a considerable cost, which justifies measuring finely.

What is the main stake in these sectors?
Reliability: preventing the stop rather than enduring it. An unplanned stop can compromise a batch, trigger requalification or disrupt a stretched supply chain, with cascading consequences far greater than the hourly impact.

How does measurement help reliability?
By making the drift readable before the breakdown. Continuous measurement detects early warning signs (slowdowns, micro-anomalies) several hours before the stop, which allows a planned intervention rather than an endured stop.

Is measurement compatible with validated processes?
Yes. The standalone measurement layer observes the machine without integrating into the heart of the regulated process, which limits the impact on validations and traceability. It brings data without upending the existing quality architecture.

How do I compare my OEE in these sectors?
With caution, by comparing real OEE figures measured the same way and equivalent realities. The goal isn’t to reach a reference percentage, but to make production reliable and recover points of high unit value.